The European Society of Medical Oncology Annual Conference (ESMO Conference) is the most prestigious and influential oncology conference in Europe; a global academic exchange platform integrating translational research and interdisciplinary discussions. This year the conference will be held virtually on September 16-21, 2021.

Geneseeq has participated in AACR, ASCO, ESMO and WCLC and other international conferences for 7 consecutive years and has so far exchanged more than 100 studies. At this year’s ESMO conference, Geneseeq will be presenting 10 e-posters in four categories: Cancer Biology, Cancer Diagnosis, Early Cancer Detection, and Minimal Residual Disease (MRD)

Category I: Cancer Biology

ePoster 40P: Evolutionary trajectories and clonal migration underlying tumor progression and lymph node metastasis in resectable lung cancer

Study highlights: This study has shown that the evolutionary subtypes of primary tumors (PTs) and the clonal evolutionary origin of lymph node metastases (LNMs) can be used as prognostic markers for lung cancer patients. Evolutionary genomics has certain clinical significance in understanding tumor progression and disease management.

ePoster 298P: Clinical implication of gene alterations revealed by comprehensive genomic profiling and clonal hematopoiesis in breast cancer patients with postoperative recurrence

Study highlights: This study showcases the value of baseline tumor tissue gene mutations and dynamic monitoring of plasma gene mutation evolution patterns in the prognosis of breast cancer patients. It also shows that the detection of clonal hematopoietic-related mutations does not affect the prognosis of patients. 

ePoster 1153P: Classification of multifocal lung adenocarcinomas subtypes using next-generation sequencing in pN0M0 lung adenocarcinomas

Study highlights: This study used comprehensive histologic assessment (CHA) and next-generation sequencing (NGS) to characterize the multifocal lung adenocarcinoma (MLA) classification of pN0M0 lung adenocarcinoma patients. The results show that there are differences between the diagnosis results of the two methods, suggesting that the molecular biology method can be combined with CHA to supplement the classification of MLA subtypes.


Category II: Cancer Diagnosis

ePoster 374P: A real-world application of aqueous humor and vitreous fluid for the diagnosis of vitreoretinal lymphoma and treatment monitoring

Study highlights: Aqueous humor and vitreous fluid can be used as an important sample source for the molecular diagnosis of vitreoretinal lymphoma (VRL) and has excellent clinical application value in the evaluation of therapeutic efficacy and disease recurrence monitoring.

ePoster 67P: Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer

Study highlights: Pathogenic BRCA1/2 mutations are currently the main biomarkers of homologous recombination defects (HRD), used in the selection of PARP inhibitors (PARPi), and it has been reported to be related to the efficacy of platinum (Pt) chemotherapy. However, patients without BRCA1/2 mutations can also exhibit HRD phenotypes through other mechanisms and may benefit from PARPi or Pt chemotherapy. This study reported that based on the NGS assessment of homologous recombination deficiency (HRD) profiles of different cancers, HRD ≥ 38 indicated HRD positive and it was related to the efficacy of platinum chemotherapy.

ePoster 1266P: Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets

Study highlights: In patients with advanced lung cancer, cell-free tumor DNA (ctDNA) mutation detection in pleural fluid can overcome tumor heterogeneity and is superior in detection performance than pleural fluid precipitation and plasma samples. The NGS sequencing of tumor tissue combined with pleural fluid can fully optimize the genomic analysis of lung cancer patients, which is vastly helpful for accurate molecular mapping and targeted therapy selection for patients.


Category III: Early Cancer Detection

ePoster 392P: Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Study highlights: The study is a multi-omics early colorectal cancer screening model constructed based on five cfDNA fragment-omics features as part of Geneseeq’s DECIPHER (Detecting Early Cancer by Inspecting ctDNA Features) program. It shows ultra-high sensitivity and specificity in the screening of advanced adenoma and early colorectal cancer, providing non-invasive colorectal cancer a new cost-effective screening method.

ePoster 950P: Ultra-Sensitive and Cost-effective Method for Early Stage Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Detection Using Plasma cfDNA Fragmentomic Profiles

Study highlights: Also as part of the DECIPHER program, this study is based on whole-genome low-depth sequencing to construct a new early liver cancer screening model based on the characteristics of cfDNA fragments. The model maintains good prediction performance at ultra-low sequencing depth, showing results better than previous methods. Predictive sensitivity provides a new cost-effective detection method for the non-invasive clinical screening of liver cancer. At the same time, this method also shows good application potential in distinguishing the different pathological subtypes of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).


Category IV: Minimal Residual Disease (MRD)

ePoster 1154P: Circulating tumor DNA analysis integrating tumor clonality detects minimal residual disease in resectable non-small cell lung cancer 

Study highlights: Surgical resection is the main treatment for patients with early lung cancer. However, because traditional detection methods cannot detect minimal residual disease (MRD), some patients still have the risk of recurrence and metastasis after surgery. This study shows for non-small cell lung cancer (NSCLC) patients receiving surgical resection treatment, ctDNA dynamic monitoring combined with tumor tissue evolution analysis can prompt the patient’s MRD status and predict the risk of tumor recurrence.

ePoster 451P: Utility of Circulating Free DNA 5’-end Motif Profile in the Prediction of Pathological Response after Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer

Study highlights: Patients with locally advanced rectal cancer (LARC) may obtain pathological complete response (pCR) after receiving neoadjuvant chemoradiotherapy (neo-CRT). These patients may consider choosing “Watch & Wait”(W&W) strategy to improve their quality of life. However, currently complete clinical response (cCR) is mainly evaluated by imaging and other methods before clinical operations, which is still inconsistent with postoperative pCR. More sensitive and accurate efficacy evaluation techniques are urgently needed. At present, the end motif characteristics of plasma circulating-free DNA (cfDNA) have shown high sensitivity in early tumor screening studies. In this study, the cfDNA end motif model can effectively predict the pathological response of patients after neo-CRT treatment, and its prediction performance is better than traditional clinical evaluation methods. The cfDNA end motif model helps to select the population suitable for W&W treatment.